How to Replace the TQT Study—The Use of Concentration‐QTc Modeling to Exclude a Small Effect of a Novel Drug on QT Interval: Historical Perspective and Implementation
The Journal of Clinical Pharmacology · 2026-07 · 66 (7)
DOI: 10.1002/jcph.70237 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Journal of Clinical Pharmacology, online erschienen am 06.07.2026. Verfasst von Borje Darpo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Clario, part of Thermo Fisher Scientific, Philadelphia, PA, USA. Hauptthemen laut MEDLINE: Long QT Syndrome, Electrocardiography, Heart Rate, Models, Biological. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 56 Literaturangaben.
Abstract (Originalsprache)
The initial ICH E14 guidance described the thorough QT/QTc (TQT) study with the purpose of evaluating whether a new drug has effects on the QTc interval. Following its adoption, concentration‐QTc (C‐QTc) modeling was applied to data from TQT studies, and results were comparable with those based on a “by time point” analysis. In 2014, the IQ‐CSRC study demonstrated that a small study in healthy subjects using C‐QTc as the primary analysis could detect mild drug‐induced QTc prolongation. The study led to the revision of the E14 guidance in 2015, allowing the use of C‐QTc modeling to exclude a QTc effect at the threshold of concern, 10 ms. The 2015 revision was the starting point for the use of C‐QTc modeling applied to data from first‐in‐human (FIH) studies with the intent to waive requests for a designated TQT study. The 2022 revision (S7B/E14 Q&A) brought non‐clinical studies into the decision process for a “definitive” QT evaluation. In this manuscript, the emergence of C‐QTc analysis applied to FIH studies with the intent to waive the TQT study is described, and a survey of FDA labels and reviews of approved drugs since 2015 is shared. The uptake has been modest, with only 30% of approved drugs for which a TQT study would be expected using this approach, while a TQT study has been conducted in ∼70% of development programs. It can be expected that the 2022 S7B/E14 revision will increase the number of programs for which a TQT study can be replaced.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Clario, part of Thermo Fisher Scientific, Philadelphia, PA, USA.
- Statistik Georg Ferber GmbH, Riehen, Switzerland.
- Newleos Therapeutics, Boston, MA, USA.
- Basilea Pharmaceutica International Ltd, Allschwil, Switzerland.
- Global Drug Development Consulting LLC, San Juan, Puerto Rico.
ORCID-Profile: Borje Darpo
Zitieren
APA
Darpo, B., Ferber, G., Hopkins, S. C., Litherland, K., Sarapa, N., Xue, H., & Kleiman, R. (2026). How to Replace the TQT Study—The Use of Concentration‐QTc Modeling to Exclude a Small Effect of a Novel Drug on QT Interval: Historical Perspective and Implementation. The Journal of Clinical Pharmacology, 66(7). https://doi.org/10.1002/jcph.70237
Vancouver
Darpo B, Ferber G, Hopkins SC, Litherland K, Sarapa N, Xue H, et al. How to Replace the TQT Study—The Use of Concentration‐QTc Modeling to Exclude a Small Effect of a Novel Drug on QT Interval: Historical Perspective and Implementation. The Journal of Clinical Pharmacology. 2026;66(7). doi:10.1002/jcph.70237
BibTeX
@article{Darpo2026,
author = {Darpo, Borje and Ferber, Georg and Hopkins, Seth C and Litherland, Karine and Sarapa, Nenad and Xue, Hongqi and Kleiman, Robert},
title = {How to Replace the TQT Study—The Use of Concentration‐QTc Modeling to Exclude a Small Effect of a Novel Drug on QT Interval: Historical Perspective and Implementation},
journal = {The Journal of Clinical Pharmacology},
year = {2026},
volume = {66},
number = {7},
doi = {10.1002/jcph.70237}
}
EUVIMED